Afya Limited

Afya Limited

29.24
BRL
+0.80
(+2.81%)
4.41EPS
8.05P/E
6.38BMarket Cap
Mar 18Next Earn
Afya Limited
B3:A2FY34
(B3)

Recent

price

29.24

P/E

ratio

8.05

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
BRL
1.2
1.85
4.8
6.29
8.93
12.57
15.54
17.79
19.83
21.27
Revenue per Share
0.25
0.48
0.98
1.53
1.16
2.02
2.09
3.4
4.04
4.35
Basic EPS, GAAP
0.1
0.32
1.13
1.22
1.84
2.95
4.31
5.6
6.26
6.41
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.26
2.78
11.17
14.5
15.54
17.26
19.43
22.96
26.2
27.75
Book Value per Share
0.23
-1
4.07
1.09
-5.02
-4.55
-6.44
-6.79
-3.98
-2.93
Tangible Book Value per Share
181
181
157
191
193
185
185
186
186
183
Basic Weighted Avg Shares
216
334
751
1,201
1,719
2,329
2,876
3,304
3,697
3,883
Sales/Revenue/Turnover
22.84
28.78
26.44
30.11
25.45
28.51
26.67
30.63
32.81
32.83
Operating Margin (%)
4
9
73
109
154
206
290
333
373
369
Depreciation Expense
45
86
154
292
223
374
386
632
752
793
Net Income, GAAP
4.9
4.04
7.58
8.08
11.4
8.33
5.63
4.06
10.74
11.31
Effective Tax Rate (%)
21.01
25.86
20.5
24.32
12.99
16.04
13.43
19.11
20.35
20.43
Profit Margin (%)
9
-49
779
816
440
732
145
450
1,058
1,165
Working Capital
3
51
269
962
1,994
2,475
2,459
2,764
3,004
2,955
LT Debt
47
590
2,114
2,834
3,000
3,250
3,643
4,311
4,891
5,097
Total Equity
- -
25.42
12.02
10.29
8.48
10.91
11.82
14.06
13.81
13.83
Return on Invested Capital (%)
- -
22.34
11.92
10.59
7.88
11.13
11.92
13.99
14.57
15.02
Return on Capital (%)
- -
31.51
11.99
12.05
7.79
12.15
11.36
16.05
16.5
16.19
Return on Common Equity (%)

Capital Structure

BRL

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
188
184
262
LT Borrowings
1,992
1,922
1,922
LT Finance Leases
1,022
1,013
1,032
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
183
182
182
Market Capitalization
7,208
7,214
6,376

Working Capital

BRL

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,224
1,950
2,240
Cash, Cash Equivalents & STI
1,333
1,006
1,289
Accounts Receivable, Net
778
820
833
Inventories
- -
- -
- -
Total Current Liabilities
1,247
886
1,075
Payables & Accruals
655
337
357
ST Debt
188
184
262
Deferred Revenue
151
104
153

Growth Rates

BRL

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
11.62%
13.47%
Free Cash Flow
- -
38.87%
12.26%
Net Income, GAAP
- -
25.95%
19.15%
Sales/Revenue/Turnover
- -
25.77%
11.89%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
804
810
841
849
3,304
2025
936
919
929
913
3,697
2026
1,013
972
985
- -
- -

Quarterly Earnings Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.1
0.85
0.65
0.83
3.4
2025
1.35
0.92
0.83
0.96
4.04
2026
1.4
1.08
0.91
- -
- -

Quarterly Dividends Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Afya Limited operates as a leading medical education group and medical practice solutions provider in Brazil. Founded in 1999 and headquartered in Nova Lima, Minas Gerais, the company offers a comprehensive portfolio of products and services organized into three main segments: Undergraduate education, Continuing Education, and Medical Practice Solutions. The Undergraduate segment comprises medical school and other health science undergraduate programs. The Continuing Education segment provides medical education including residency preparation programs, specialization test preparation, graduate courses, and other medical capabilities delivered through digital and in-person content. The Medical Practice Solutions segment offers clinical decision support, clinical management, and doctor-patient relationship solutions, mainly through brands such as Pebmed and iClinic, supporting healthcare professionals and institutions. Afya operates medical schools across various locations in Brazil, including newly expanded operations in Minas Gerais. Recent major changes include the acquisition of Faculdade Única de Contagem (FUNIC), adding 60 medical school seats with potential for an additional 60 seats contingent on Ministry of Education approval, marking expansion in Minas Gerais and strengthening Afya’s footprint as its fifth medical school in the state. The acquisition aligns with Afya’s strategic focus on growth through expanding medical education capacity and consolidating its ecosystem integrating education and medical practice solutions. Additionally, Afya restructured its continuing education segment in 2024 by consolidating various entities such as Medcel, Além da Medicina, CardioPapers, and Medical Harbour under one segment to better integrate content and technology for medical education. The company launched five new specialization campuses in 2024, reinforcing its continuing education and medical practice solutions growth strategies. Afya targets medical students, residents, physicians, and healthcare professionals across Brazil, providing an integrated ecosystem that supports the entire physician career journey. The company reported significant revenue growth and operational efficiencies with a strong focus on digital transformation and academic excellence. As of 2025, Afya has around 26,000 medical students, monthly active users of 228,000, and over 304,000 users within its ecosystem. Financially, Afya expects strong future cash flows with an enterprise value to EBITDA multiple anticipated at 3.3x by 2030 following full synergy realization from acquisitions and organic growth. Overall, Afya Limited is positioned as a dominant player in Brazil's medical education sector, combining undergraduate medical programs, advanced continuing education services, and practice management solutions to serve the healthcare education and medical practitioner markets nationwide. Their strategic expansions and restructuring efforts in recent years underscore their commitment to becoming the primary educational and professional development resource for medical professionals in Brazil.

Company News

  • Afya: The Drop Came From Brazil, Not From The Company (Buy Rating)

  • Afya: 3 Key Takeaways for Long-Term Investors

  • Afya Limited (AFYA) Q3 2026 Earnings Call Transcript

  • What Afya (AFYA) Said on Its Q3 Earnings Call

  • Afya (AFYA) Q3 Earnings Lag Estimates

  • Afya Limited Announces Third Quarter and Nine Months 2026 Financial Results

  • Afya (AFYA) Earnings Expected to Grow: Should You Buy?

  • Afya (NASDAQ:AFYA) Shares Cross Below Two Hundred Day Moving Average – Here’s What Happened

  • Afya Maps Yduqs Merger, BRL 2.2B Synergies and Digital Health Growth at Investor Day

  • Afya Limited (AFYA) Analyst/Investor Day Transcript

  • AFYA or UTI: Which Is the Better Value Stock Right Now?

  • Should Value Investors Buy Afya (AFYA) Stock?

  • Is It Too Late to Buy Afya Ltd (AFYA) After 4.5% Rally? GF Value Says Undervalued

  • Merger Agreement and Other Covenants Entered Into by and Between AFYA LIMITED and YDUQS PARTICIPAÇÕES S.A.

  • Afya Limited and YDUQS Participações S.A. Controlling Shareholders Enter Into Voting Commitment Agreement

  • Afya Limited to Host Afya Day 2026 on October 20th in Rio de Janeiro

  • Afya Limited (NASDAQ:AFYA) Shares Shorted: Short Interest Up 163.2% in September

  • Afya (NASDAQ:AFYA) Hits New 12-Month Low – Here’s What Happened

  • Afya Limited (NASDAQ:AFYA) Stock Rated “Hold” by Wall Street Brokerages

  • Afya Limited (AFYA) M&A Call Transcript